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During 6 months, we obtained Enterobacteriaceae isolates from patients with gram-negative bacteremia at a
1,250-bed teaching hospital in St. Louis, MO, and compared carbapenem susceptibilities with the presence of
blaKPC, a transferable carbapenemase gene. Three (1.2%) out of 243 isolates were blaKPC positive. Ertapenem
nonsusceptibility had a low positive predictive value.
The serine carbapenemase KPC (Klebsiella pneumoniae car-
bapenemase) has emerged as a beta-lactamase capable of in-
activating carbapenem antibiotics. First identified in Klebsiella
pneumoniae (21), KPC has since been detected in other Entero-
bacteriaceae (7). The gene encoding KPC, blaKPC, is plasmid
transmissible among Enterobacteriaceae, which has implica-
tions for infection control (3, 20). The presence of blaKPC may
not always result in carbapenem resistance in vitro (19),
thereby impeding detection during routine workup. KPC-pro-
ducing bacteria have primarily been reported from the New
York City area; however, blaKPC is present among Enterobac-
teriaceae isolates as far west as Arkansas (7). The aim of this
study was to systematically screen Enterobacteriaceae bactere-
mia isolates for reduced susceptibility to carbapenems and to
correlate results with the presence of blaKPC.
(This work was presented in abstract form at the 47th Inter-
science Conference on Antimicrobial Agents and Chemother-
apy, Chicago, IL, September 2007 [12a].)
Microbiological and molecular analyses were performed on
bacterial isolates from inpatients with Enterobacteriaceae bac-
teremia at Barnes-Jewish Hospital in St. Louis, MO. We in-
cluded patients with bacteremia occurring between 1 August
2006 and 31 January 2007. Isolates were tested for susceptibil-
ity to the three carbapenem antibiotics (ertapenem, imipenem,
and meropenem) and noncarbapenem antibiotics, using the
disk diffusion method (6) (Sensi-Disc antibiotic disks; Becton
Dickinson and Co., Sparks, MD).
Total DNA was extracted using the QIAamp DNA minikit
(Qiagen, Valencia, CA). A real-time PCR assay of all available
isolates (n  243) was developed for initial screening for the
presence of blaKPC using primers and cycle parameters as
described previously (17). All isolates that were positive for the
blaKPC gene by real-time PCR were confirmed with a conven-
tional PCR assay as described previously (5). The three posi-
tive isolates were further characterized by DNA sequencing of
the blaKPC PCR product using primers (forward, 5-ATGTCA
CTGTATCGCCGTC-3; reverse, 5-CTCAGTGCTCTACAG
AAAACC-3) and thermocycling parameters described by
Yigit et al. (21), with a BigDye Terminator cycle sequencing
kit, v3.1 (Applied Biosystems Inc., Foster City, CA) in an MJ
Research PTC-200 DNA Engine thermal cycler (Bio-Rad Lab-
oratories, Waltham, MA). Sequencing reaction mixtures were
purified by ethanol precipitation, separated, and analyzed us-
ing an ABI Prism 3100 genetic analyzer (ABI, Foster City, CA)
following the manufacturer’s protocols. Forward and reverse
strands of two independent PCR products from each isolate
were sequenced. Sequences were aligned and compared to
published sequences for the blaKPC-2 gene using Vector NTI
v10.3.0 software (Invitrogen, Carlsbad, CA) and found to be
identical to the blaKPC-2 published sequence.
Patient data on demographics, comorbidities, treatment,
and in-hospital mortality were abstracted from medical
records. The Washington University Human Research Protec-
tion Office approved this study.
During the study period, 247 Enterobacteriaceae isolates
were recovered from blood cultures at Barnes-Jewish Hospital.
Four isolates were unavailable for testing, leaving 243 Entero-
bacteriaceae isolates from 223 patients. Ninety isolates (37.0%)
were Escherichia coli, 79 (32.5%) were Klebsiella pneumoniae,
25 (10.3%) were Enterobacter spp., 13 (5.3%) were Proteus
mirabilis, 11 (4.5%) were Klebsiella oxytoca, 7 (2.9%) were
Citrobacter spp., 6 (2.5%) were Serratia marcescens, and 12
(4.9%) were other species. Seven (2.9%) isolates had reduced
susceptibility to one or more carbapenems (Table 1). Two
isolates were resistant to all carbapenems tested; both were
blaKPC positive. Three isolates were nonsusceptible only to
ertapenem; none of these were blaKPC positive.
Three (1.2%) isolates carried the blaKPC gene. These iso-
lates infected three patients (Table 2) and included one K.
pneumoniae, one Enterobacter cloacae, and one P. mirabilis
isolate. The in vitro ertapenem nonsusceptibility assay de-
tected blaKPC with high sensitivity (100% [three/three]) and
high specificity (98.3% [236/240]), similar to results for imi-
penem (100% [three/three] and 100% [240/240], respectively)
and meropenem (66.6% [two/three] and 99.6% [239/240], re-
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spectively) (Table 1). The positive predictive value (PPV) of
ertapenem nonsusceptibility for detecting blaKPC was 43%
(three/seven) versus 100% (three/three) for imipenem and
66.6% (two/three) for meropenem. The PPV of ertapenem as
sole carbapenem showing resistance was 0% (zero/three); the
PPV of resistance to all three carbapenems for detecting
blaKPC was 100% (two/two). One (33%) of the patients in-
fected with a blaKPC
 isolate and 41 (18.6%) of the patients
infected with a blaKPC
 isolate died.
KPC-positive bacteria were present in 1.3% (3/223) of bac-
teremia episodes in our study, which is relatively low. However,
plasmid transfer and subsequent dissemination can occur (3,
21). In a study by Landman et al., the susceptibility of K.
pneumoniae isolates to carbapenems decreased from 97% to
76% within 5 years, probably due to blaKPC (11). In a United
States-wide surveillance study, the prevalence of blaKPC among
various Enterobacteriaceae was 0.5% (7), whereas a study of
Brooklyn hospitals reported 38% prevalence in K. pneumoniae
(11). Our data confirm that blaKPC is not restricted to the
northeastern United States and warrant surveillance of carbap-
enem susceptibilities among Enterobacteriaceae.
Ertapenem has been proposed as the carbapenem that most
accurately detects the presence of blaKPC by disk diffusion (1,
4, 12). This may be because diameter cutoffs for inhibition
zones were set more stringently for ertapenem than for other
carbapenems (6). Ertapenem was the most frequently nonsus-
ceptible carbapenem in our study; however, the PPV of ertap-
enem nonsusceptibility for identifying blaKPC was low (43%).
This is possibly due to carbapenem resistance mediated by
mechanisms other than blaKPC (16). Other studies (15, 19)
have found that carbapenem susceptibility testing by the disk
diffusion method is unreliable at predicting the presence of
blaKPC. Possible explanations for undetected blaKPC carriage
are an unexpressed blaKPC gene, the inoculum effect (4), and
misinterpretation of the resistance pattern to signify an extend-
ed-spectrum beta-lactamase producer (15). An MIC that is in
the upper range of susceptibility may be the only indication of
blaKPC. Lowering the imipenem MIC breakpoints (13) or
PCR-based screening (2, 9) might increase the chance of de-
tecting resistance.
A limitation of our study is that we did not assess isolates for
additional beta-lactamases other than blaKPC, which is a con-
stellation increasingly encountered (12, 14). We also had a
relatively small sample size and a single-center design, and we
restricted analysis to bacteremia isolates. We did not test gram-
negative bacteria outside the Enterobacteriaceae family for
blaKPC (18). In conclusion, our study is among the first pro-
spective investigations into the endemic epidemiology of
blaKPC-positive bacteria, demonstrating that blaKPC is cur-
rently present at a low level in a major Midwestern city. Disk
diffusion tests currently remain the simplest screening tests to
TABLE 1. Characteristics of Enterobacteriaceae strains exhibiting in vitro carbapenem nonsusceptibility and/or harboring the blaKPC gene
Source
patient Organism
Disk diffusion test result for antibiotica:
blaKPC
genotypeCarbapenem Noncarbapenem
Ertapenem Imipenem Meropenem Cefepime Ciprofloxacin Gentamicin
1 K. pneumoniae R R R R R S 
K. pneumoniae R S R 
2 E. cloacaeb R R R R S S 
E. cloacae R S S 
3 P. mirabilis I R S S S S 
E. coli R S S 
Citrobacter freundii I S S 
a S, susceptible; I, intermediate; R, resistant. In additional susceptibility testing, the K. pneumoniae isolate recovered from patient 1 was intermediately susceptible
to tigecycline and susceptible to colistin. Also, the E. cloacae isolate from patient 2 was intermediately susceptible to tigecycline and susceptible to colistin.
b Recovered from a patient with polymicrobial Enterobacteriaceae bacteremia.




















































Non-ICU Skin/soft tissue Community acquired,
health care
associated
P. mirabilis Yes (piperacillin-
tazobactam)
Recovered
a ICU, intensive care unit; PVD, peripheral vascular disease; DM, diabetes mellitus. A bacteremia was considered hospital acquired if it occurred 48 h after
admission. Community-acquired infections were defined as health care associated by using published criteria (8). Inadequate empirical antibiotic treatment was defined
as no antibiotic being given to which the bacteria were susceptible within 24 h of the positive blood culture being obtained (10).
b Recovered from a patient with polymicrobial Enterobacteriaceae bacteremia.
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detect blaKPC-positive bacteria in clinical microbiology labora-
tories.
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